- KEYNOTE-C87 is intended to support accelerated approval and/or a full licensure
- Study addresses a high unmet medical need in certain patients with metastatic melanoma for whom there are no FDA approved treatment options
PR Newswire
PENNINGTON, N.J. and SAN DIEGO, July 6, 2021